Pharmaceutical composition comprising a) a compound Granules with Derivative of imidazo [4,5-c] quinoline, b) at least one nonionic Surfactant is Vitamin E TPGS and (c) at least one Improver Dissolution； production process； kit； and use to treat a disease proliferativ To or dependent of mTOR Kinase.
CAO YU,HACKL WOLFGANG,LI PING,LI SHOUFENG,MIRZA TAHSEEN,ZEHENDER HARTMUT,ZHU JIAHAO
申请号：
CL2013001557
公开号：
CL2013001557A1
申请日:
2013.05.31
申请国别(地区):
CL
年份:
2013
代理人:
摘要：
A pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), comprising granules that comprise at least therapeutic compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof； at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition； and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing； processes for making such pharmaceutical compositions； a kit comprising such pharmaceutical composition and the instructions for administration thereof； and related uses and methods of treatment.COMPOSICION FARMACEUTICA QUE COMPRENDE GRANULOS CON A) UN COMPUESTO DERIVADO DE IMIDAZO[4,5-C]QUINOLINA, B) POR LO MENOS UN TENSOACTIVO NO IONICO QUE ES LA VITAMINA E TPGS Y C) POR LO MENOS UN AGENTE MEJORADOR DE DISOLUCION； PROCESO DE ELABORACION； KIT； Y USO PARA TRATAR UNA ENFERMEDAD PROLIFERATIVA O DEPENDIENTE DE LA CINASA MTOR.
